Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score

This pilot study was aimed to assess the percentage of patients admitted to a Russian hospital and diagnosed with heart failure with preserved ejection fraction (HFpEF) maintaining this diagnosis when evaluated against the ESC 2016 and Russian 2017 heart failure guidelines. In addition, we reviewed the probability of an HFpEF diagnosis when patients were assessed against the H2FPEF score. Forty-two patients (mean age 68 ±7,5) diagnosed with HFpEF on their discharge record, admitted between March 2018 and May 2018, were included. Twenty percent of patients did not meet Russian guideline criteria for HFpEF due to either the absence of symptoms and/or echocardiographic evidence of structural/functional abnormalities. Using the ESC 2016 guidelines (which required an elevation in NT Pro BNP) the diagnosis was confirmed in only 37% of patients, mostly due to the normal level of NTproBNP in 54.8% of those investigated. The probability of HFpEF by H2FPEF score in patients with dyspnea and HFpEF by ESC 2016 criteria was 93% and without HFpEF by ESC 2016 criteria 68% (p = 0.054). In contrast, the probability of HFpEF by H2FPEF score in patients with dyspnea and HFpEF by Russian criteria was 84.4%.

1. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2017; 14(10): 591–602. DOI:10.1038/nrcardio.2017.65

2. Mareev Yu.V., Mareev V.Yu. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(4S):20–30. [Russian]. DOI:10.18087/cardio.2433

3. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016;37(5):455–62. DOI:10.1093/eurheartj/ehv464

4. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure. 2018;20(8):1230–9. DOI:10.1002/ejhf.1149

5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI:10.1093/eurheartj/ehw128

6. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58 (6S): 8–164. [Russian]. DOI:10.18087/cardio.2475

7. Parekh N, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Current Opinion in Cardiology. 2009;24(2):155–60. DOI:10.1097/HCO.0b013e328320d82a

8. Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M et al. Prevalence, Clinical Phenotype, and Outcomes Associated with Normal B-Type Natriuretic Peptide Levels in Heart Failure with Preserved Ejection Fraction. The American Journal of Cardiology. 2012;110(6):870–6. DOI:10.1016/j.amjcard.2012.05.014

9. Obokata M, Kane GC, Reddy YNV, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous InvasiveEchocardiographic Study. Circulation. 2017;135(9):825–38. DOI:10.1161/CIRCULATIONAHA.116.024822

10. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. Circulation. 2018;138(9):861– 70. DOI:10.1161/CIRCULATIONAHA.118.034646

11. H2FPEF Score for Heart Failure with Preserved Ejection Fraction. [Internet] Available at: https://www.mdcalc.com/h2fpef-score-heart-failure-preserved-ejection-fraction

12. R: The R Project for Statistical Computing. [Internet] Available at: https://www.r-project.org/

13. Garganeeva A.A., Kuzheleva E.A., Kuzmichkina M.A., Ryabov V.V., Mareev Yu.V., Mareev V.Yu. Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016. Kardiologiia. 2018;58 (12S): 18–26. [Russian]. DOI:10.18087/cardio.2605

14. Kirillova V.V., Sokolova L.A., Meshchaninov V.N., Pershanova V.I. The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle. Therapeutic Archive. 2018;90 (9):68–72. [Russian]. DOI:10.26442/terarkh201890968-72

15. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. DOI:10.1161/CIRCULATIONAHA.114.013255

16. Bristow MR, Silva Enciso J, Gersh BJ, Grady C, Rice MM, Singh S et al. Detection and Management of Geographic Disparities in the TOPCAT Trial. JACC: Basic to Translational Science. 2016;1(3):180–9. DOI:10.1016/j.jacbts.2016.03.001

17. Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC et al. Association of Natriuretic Peptides with Cardiovascular Prognosis in Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiology. 2018;3(10):1000. DOI:10.1001/jamacardio.2018.2568

18. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. International Journal of Cardiology. 2014;176(3):611–7. DOI:10.1016/j.ijcard.2014.08.007

19. Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Failure Reviews. 2012;17(1):81–96. DOI:10.1007/s10741-011-9249-z

20. Rubanenko O.A. Nt-proBNP and C-reactive protein as predictors of atrial fibrillation in coronary bypass surgery. Russian Heart Journal. 2016;15(2):88–92. [Russian]. DOI:10.18087/rhj.2016.2.2164

21. Snezhitskiy V.A., Bubeshka D.A., Hryb S.N., Madekina G.A. Correlation of N-terminal pro-brain natriuretic peptide level and recurrences of nonvalvular atrial fibrillation. Journal of the Grodno State Medical University. 2017;15 (2):198–204. [Russian]

22. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J et al. N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients with Atrial Fibrillation. Journal of the American College of Cardiology. 2013;61(22):2274–84. DOI:10.1016/j.jacc.2012.11.082

23. Oshchepkova E.V., Lazareva N.V., Satlykova D.F., Tereshchenko S.N. The first results of the Russian register of chronic heart failure. Kardiologiia. 2015;55 (5):22–8. [Russian]

24. Kaplon Cieslicka A, Laroche C, Andarala M, Crespo-Leiro MG, Coats AJS, Anker SD et al. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the ESC-HF LongTerm Registry. European Heart Journal. 2018;39(suppl_1):472. DOI:10.1093/eurheartj/ehy565.2457

25. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2016;29(4):277–314. DOI:10.1016/j.echo.2016.01.011